IDEXX Laboratories set to report Q2 earnings amid market underperformance
Consensus estimates point to diluted earnings per share of $3.95 for the fiscal second quarter, but shares have lagged the broader market over the past year.
IDEXX Laboratories, the Westbrook, Maine-based veterinary diagnostics leader, is scheduled to release its fiscal second-quarter 2026 earnings before market open on Tuesday, 4 August. The company, which holds a market capitalisation of $44.6 billion, develops and distributes diagnostic products for companion animal, livestock, poultry, dairy, and water testing markets.
Analysts anticipate diluted earnings per share of $3.95 for the quarter, representing an 8.8 per cent increase from the $3.63 recorded in the same period last year. For the full fiscal year 2026, consensus estimates project EPS of $14.68, up 12.2 per cent from fiscal 2025. Looking ahead, EPS is expected to rise 12.6 per cent year-on-year to $16.53 in fiscal 2027.
Despite these projections, the stock has underperformed the S&P 500 Index over the past 52 weeks. IDEXX shares have risen just 4.2 per cent during this period, compared to the S&P 500’s 20.6 per cent gains. The underperformance has also been evident against the State Street Health Care Select Sector SPDR ETF, which returned 18 per cent over the same timeframe.
Investors have expressed concern over slowing companion animal growth and weaker demand following the post-pandemic boom. These factors, combined with foreign exchange headwinds and uneven international demand, have added pressure to revenue. Nevertheless, IDEXX has surpassed Wall Street’s EPS estimates in each of its last four quarterly reports.
Analysts maintain a 'Moderate Buy' consensus rating on the stock. Of the 15 analysts covering IDEXX, eight hold a 'Strong Buy' rating, one suggests a 'Moderate Buy', and six advise a 'Hold'. The average analyst price target is $720.86, implying a potential upside of 27.9 per cent from current levels.
